ANGLE plc

ANGLE plc

ANGLE plc was founded in 1996 by Andrew Newland in Guildford, England, as an R&D company focused on developing a platform to harvest circulating tumor cells from blood samples. The company listed on the AIM market of the London Stock Exchange in 2004 (ticker: AGL) and now employs approximately 100 people across its UK headquarters and a US subsidiary in Pennsylvania. The Parsortix system is the firm's core technology — a microfluidic device that captures intact tumor cells from a blood sample without labels. ANGLE has built a proprietary workflow for downstream genomic and protein analysis of those cells, targeting applications in cancer diagnosis, treatment selection, and therapy monitoring. The firm has pursued US Food and Drug Administration clearance, receiving a Breakthrough Device Designation in 2019; a pivotal clinical trial for FDA clearance was completed in 2022. Revenue is generated through instrument sales, consumable kits, and services provided to pharmaceutical companies and academic researchers. As of 2025, ANGLE had placed over 500 Parsortix instruments globally, primarily in research labs. The company has reported accumulated losses since inception, typical of a diagnostics development company at this stage. In 2023, the firm raised £12.2 million via a share placing to fund its clinical and regulatory pathway. ANGLE's structural differentiator is its focus on a specific liquid biopsy technology — CTC capture rather than the commonly targeted circulating tumor DNA — and its pursuit of FDA clearance as a class II medical device. The business model combines hardware, consumables, and clinical service revenue, which is rare among diagnostic developers targeting the same indication.